This, despite the fact that research has demonstrated that ketamine actually shrinks brain tissue. A scientific study found that gray matter volume decreased in users of ketamine, especially in adolescents, stating: “Our results suggest that early ketamine exposure has more impact on the developing brain.”
This, also despite the fact that the FDA states that “ketamine is not FDA approved for the treatment of any psychiatric disorder.”
Nonetheless, the study, called “A Preliminary Trial of Safety and Feasibility of Ketamine-assisted Psychotherapy in Adolescents With Posttraumatic Stress Disorder,” is moving forward. Five adolescents who allegedly have PTSD will be juiced up three times with intravenous ketamine and given psychotherapy “treatment” after each ketamine trip, just to see what happens.
It doesn’t take a brain like Einstein’s to see how utterly crazy this is.
Think of it: Millions of prescriptions and appointments, with the bills just slithering right into your wallet.
Is ketamine even remotely safe? Not according to the FDA.
“FDA is aware that compounded ketamine products have been marketed for a wide variety of psychiatric disorders,” the government health agency stated, “however, FDA has not determined that ketamine is safe and effective for such uses.”
Side effects of ketamine include blood pressure increase, disorientation, confusion, loss of motor coordination, dizziness, vomiting, changes in sensory perception and hallucinations, or feelings of detachment from yourself and your environment.
Severe detachment, from even your own body, is described as “falling into a K-hole,” and can result in coma or even death.
So, how safe is ketamine? Matthew Perry, the former star of Friends, found out in 2023—the drug killed him.
Why would psychiatrists and psychologists promote this dangerous nonsense?
“The current push for these psychedelic substances is a hallmark of profit-driven tactics by the pharmaceutical industry, psychiatrists and unregulated psychedelic clinics—ultimately exposing Americans to more damaging mind-altering drugs,” wrote the Citizens Commission on Human Rights.
Profit—that’s the key. In 2020, about 13 million Americans were said to suffer from PTSD. Imagine how profitable it would be for a company to win government approval of ketamine to “treat” it. Think of it: Millions of prescriptions and appointments, with the bills just slithering right into your wallet.
The Usona Institute, a nonprofit offshoot of the for-profit Promega Corporation, smelling the potential of those huge profits, just built a $72 million, 93,000-square-foot, 17-acre “therapy, training and education center,” and is trying to get psilocybin—or magic mushrooms—approved for treatment of various mental conditions.
But there’s no question the University of Wisconsin plans to become the academic leader in psychoactive “therapy.”
The university even launched the master’s program “Pharmaceutical Sciences: Psychoactive Pharmaceutical Investigation.” The program is “designed to better prepare recent grads and working professionals for a career in the discovery, development and clinical application of psychoactive drugs as therapeutic agents.”
Just great—a whole master’s degree program to train more drug pushers. Exactly what we need, right?
But now that “nonprofits” and universities are spending all that money, what’s going to happen when their greedy bubble bursts?
In last year’s election, pro-drug forces, groups fighting for the legalization of ayahuasca, ketamine, mescaline, DMT and all sorts of wacky psychotropic, brain-scrambling drugs, spent tons of money in several states—only to see their psychedelic dreams spiral down the toilet as American voters roundly defeated them at the polls.
Face it: The vast majority of Americans just don’t want this.
The FDA already turned down MDMA, a psychoactive drug known as Ecstasy, and the University of Wisconsin was involved in the failed application.
You see, one by one, psychiatrists have seen their moneymakers collapse: frontal lobotomy, heavyweight medications to stun patients into comatose zombies, electroshock—all trending toward becoming fatal relics of yesteryear.
So psychiatrists’ latest wish for a steady paycheck is psychedelic therapy. They claim it can cure everything from depression to PTSD to anxiety—maybe even ingrown toenails and dandruff, who knows? (All that matters is it’s the new “magic bullet” that will buoy their bank accounts.)
But people are wising up. Psychiatry’s salad days are numbered.
It’s about time.
